跳至主要内容
临床试验/ACTRN12617000391370
ACTRN12617000391370招募中2 期

Role of Tranexamic acid on post operative blood loss and blood transfusion in intra capsular neck of femur fracture patients undergoing hip arthroplasty (total hip arthroplasty or hemiarthroplasty)

epean Hospital (Nepean Blue Mountain Local Health District)0 个研究点目标入组 250 人开始时间: 2017年3月16日最近更新:

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
250

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Patients with intra-capsular neck of femur fractures undergoing hemiarthroplasty (cemented or uncemented) or total hip arthroplasty (cemented, hybrid or uncemented) within 48 hrs from the time of injury.

排除标准

  • 1.Neck of femur fractures requiring fixation by other methods e.g. by cannulated screws, dynamic hip screw or intra-medullary nail device.
  • 2.Patients presenting 48 hours from the time of injury. This includes patients transferred to Nepean hospital from other hospitals.
  • 3.Contra-indication to the administration of TA -
  • Previous history of thrombosis
  • Active thromboembolic disease (DVT,PE and cerebral thrombosis)
  • Other contraindication to the use of TA :
  • Patients with acquired disturbances of colour vision
  • Patients with subarachnoid haemorrhage
  • Previous history of seizure
  • Creatinine clearance < 30ml/min
  • Hypersensitivity to TA
  • 4.Patients who are unable to provide informed consent.

研究者

发起方
epean Hospital (Nepean Blue Mountain Local Health District)

相似试验